Boehringer Ingelheim’s Spevigo (spesolimab) Receives the Health Canada’s Marketing Authorization for Generalized Pustular Psoriasis
- Health Canada has granted marketing authorization for Spevigo to treat adult patients with flares for generalized pustular psoriasis
- The approval was based on the 12wk. P-II trial (EFFISAYIL-1) evaluating spesolimab (900mg, IV) vs PBO in a ratio (2:1) in 53 patients which showed that 54% vs 6% of patients showed no visible pustules after 1wk. while 84.4% had no visible pustules and 81.3% with clear/almost clear skin after 12wk., inf. was reported in 17% vs 6% at 1wk.
- Spesolimab is a novel, humanized, selective Ab that blocks the activation of IL-36R. Spesolimab is also being studied for the treatment of other neutrophilic skin conditions as well as for the prevention of GPP flares
Ref: Newswire | Image: Boehringer Ingelheim
Related News:- Boehringer Ingelheim’s Spevigo (spesolimab) Receives EC’s Conditional Marketing Authorization for Generalized Pustular Psoriasis Flares
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].